New drug combo tested to shrink tumors before prostate cancer surgery
NCT ID NCT07476677
Summary
This study is testing whether taking a drug called darolutamide, with or without standard hormone therapy, before surgery can better control high-risk prostate cancer. It will involve 60 men who will receive 3-6 months of drug treatment followed by surgery. The main goal is to see if this approach reduces the amount of cancer left after surgery and improves long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 101205, China
Contact
Conditions
Explore the condition pages connected to this study.